{"schema_version":"secwatch.filing_event.v1","accession":"0001380106-26-000097","form_type":"8-K","ticker":"RPID","cik":"0001380106","company_name":"RAPID MICRO BIOSYSTEMS, INC.","filed_at":"2026-08-07T11:02:16+00:00","discovered_at":"2026-08-07T11:05:00.452806+00:00","generated_at":"2026-08-07T11:05:14.273001+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rapid Micro Biosystems Q2 2026 revenue up 11% to $8.1M; gross margin record 15%","bullets":["Q2 2026 total revenue $8.1M, +10.9% YoY; product $5.3M, service $2.8M, recurring $5.0M (+14.3%).","Gross margin 15.0% vs 3.8% YoY; net loss $12.9M ($0.27/share) vs $11.9M loss ($0.27/share) prior year.","Placed 4 Growth Direct systems, completed 9 validations; 200th system placed globally.","Reaffirms FY2026 revenue guidance $37-41M, 30-38 placements, ~20% gross margin; raises validation guidance to at least 27.","Cash, equivalents and short-term investments ~$20M as of June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001380106-26-000097","json":"https://secwatch.observer/filing/0001380106-26-000097.json","markdown":"https://secwatch.observer/filing/0001380106-26-000097.md","text":"https://secwatch.observer/filing/0001380106-26-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1380106/000138010626000097/0001380106-26-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1380106/000138010626000097/rpid-20260807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-07T11:05:14.273001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}